<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03735433</url>
  </required_header>
  <id_info>
    <org_study_id>OBASA</org_study_id>
    <nct_id>NCT03735433</nct_id>
  </id_info>
  <brief_title>The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia</brief_title>
  <official_title>The Effect of 81mg vs 162mg ASA for Preeclampsia Prevention in Obese Women at High Risk for Developing Preeclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low dose aspirin (LDA) is used for preeclampsia (PE) prevention in high risk women, but the
      precise mechanism and optimal dose is not known. Evidence in the non-obstetric literature
      suggests AR may be more common among patients with a high body mass index (BMI). Recent
      unpublished data showed that LDA substantially lowers TxB2 levels regardless of BMI, but
      rates of complete platelet inhibition are lower in women with BMI â‰¥40. This data suggests
      that higher doses of ASA may be necessary in obese women. Therefore we plan determine if use
      of 162mg compared to the traditional 81mg ASA decreased rates of preeclampsia in women
      considered high risk for developing preclampsia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evidence suggests that an imbalance in prostacyclin and thromboxane A2 (TxA2) plays a key
      role in PE. Aspirin (ASA) has a dose-dependent effect blocking production of TxA2, a potent
      stimulator of platelet aggregation (PA) and promoter of vasoconstriction. Incomplete
      inhibition of PA, designated aspirin resistance (AR), can be reduced by increasing the ASA
      dose.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Diagnosis of preeclampsia</measure>
    <time_frame>Through study completion, an average for 10 months</time_frame>
    <description>by acog definitions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of aspirin resistance based on incomplete inhibition of TBx2</measure>
    <time_frame>Through study completion, an average for 10 months</time_frame>
    <description>incomplete platelet inhibition measured by urinary TBx2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>81 mg daily aspirin dose</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>obese women &gt;30 BMI at risk for preeclampsia will receive recommended 81mg ASA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>162mg daily aspirin dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>obese women &gt;30 BMI at risk for preeclampsia will receive increased dose of 162mg ASA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>162mg aspirin dose</intervention_name>
    <description>2 pills of 81mg aspirin</description>
    <arm_group_label>162mg daily aspirin dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI at enrollment &gt;/= 30

          -  plan for ASA for preeclampsia prevention

        Exclusion Criteria:

          -  BMI &lt; 30

          -  already on ASA
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Ohio State Medical Center Labor and Delivery Unit</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Rood, MD</last_name>
      <phone>440-321-0264</phone>
      <email>kara.rood@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anna Barthlomew, RN</last_name>
      <phone>614-293-5632</phone>
      <email>anna.barthlomew@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kara M Rood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 4, 2018</study_first_submitted>
  <study_first_submitted_qc>November 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>February 23, 2020</last_update_submitted>
  <last_update_submitted_qc>February 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Kara M Rood, MD</investigator_full_name>
    <investigator_title>Prinicple Investigator</investigator_title>
  </responsible_party>
  <keyword>aspirin</keyword>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

